Delle Cave Valeria, Di Dato Fabiola, Calvo Pier Luigi, Spagnuolo Maria Immacolata, Iorio Raffaele
Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples 80131, Italy.
Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza, Turin 10126, Italy.
World J Hepatol. 2024 Aug 27;16(8):1111-1119. doi: 10.4254/wjh.v16.i8.1111.
Acute liver failure (ALF) may be the first and most dramatic presentation of Wilson's disease (WD). ALF due to WD (WD-ALF) is difficult to distinguish from other causes of liver disease and is a clear indication for liver transplantation. There is no firm recommendation on specific and supportive medical treatment for this condition.
To critically evaluate the diagnostic and therapeutic management of WD-ALF patients in order to improve their survival with native liver.
A retrospective analysis of patients with WD-ALF was conducted in two pediatric liver units from 2018 to 2023.
During the study period, 16 children (9 males) received a diagnosis of WD and 2 of them presented with ALF. The first was successfully treated with an unconventional combination of low doses of D-penicillamine and zinc plus steroids, and survived without liver transplant. The second, exclusively treated with supportive therapy, needed a hepatotransplant to overcome ALF.
Successful treatment of 1 WD-ALF patient with low-dose D-penicillamine and zinc plus steroids may provide new perspectives for management of this condition, which is currently only treated with liver transplantation.
急性肝衰竭(ALF)可能是威尔逊病(WD)的首发且最为严重的表现形式。由WD引起的ALF(WD-ALF)很难与其他肝病病因相区分,且是肝移植的明确指征。对于这种情况,目前尚无关于特异性及支持性药物治疗的确切建议。
严格评估WD-ALF患者的诊断和治疗管理,以提高其自体肝脏的生存率。
对2018年至2023年期间两个儿科肝病治疗中心的WD-ALF患者进行回顾性分析。
在研究期间,16名儿童(9名男性)被诊断为WD,其中2名表现为ALF。第一名患者通过低剂量D-青霉胺、锌与类固醇的非常规联合治疗成功治愈,未进行肝移植存活下来。第二名患者仅接受支持性治疗,需要进行肝移植以克服ALF。
1例WD-ALF患者采用低剂量D-青霉胺、锌与类固醇联合治疗成功,可能为目前仅通过肝移植治疗的这种疾病的管理提供新的思路。